E-ISSN 2983-7561
 
2025, Vol: 4, Issue: 2
4 / 2Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article
Online Published: 06 Feb 2024


Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia

Muhammad Ishaq, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, Muhammad Sanowar Ali.


Cited By:1

Abstract
BACKGROUND:
Drug repurposing is an important approach to treat COVID-19 pandemic. Among various drugs that were felt efficacious we had to use the ones that were low cost, efficacious and readily available. Antibacterial drug teicoplanin has shown some promise in this regard. This study evaluates the therapeutic benefits of using teicoplanin in COVID-19 pneumonia patients.
METHODS:
In this case-control study, 39 patients of COVID-19 were included. The controls (n=19) had received azithromycin for seven days while the cases (n=20) received teicoplanin for ten days. The primary outcomes included the limitations on activity due to illness, need for hospitalization, need for supplemental oxygen therapy and/or ventilation by the 14th day of starting treatment. While the secondary outcomes included same parameters recorded on interim basis by the 7th day of starting treatment.

RESULTS:
A total of 39 patients, including 12 females and 27 males diagnosed with COVID-19 were included in this study, who had received antibacterial drugs azithromycin (n=19) or teicoplanin (n=20) as part of the treatment. The teicoplanin group had a consistently lower prevalence of fever on days 7, 10 and 15 (p <0.001, <0.001 and 0.02 respectively). Despite suffering from a severer form of the disease, the teicoplanin group showed a rapid recovery in terms of cough and shortness of breath. Similarly, they had a significantly better recovery from the loss of smell sensation by day 15 (p=0.039).
CONCLUSIONS:
Teicoplanin use is associated with rapid recovery from febrile illness as well as improvement in clinical and biochemical features in moderate-to-severe COVID-19 pneumonia.

Key words: COVID-19, SARS-CoV-2, Pneumonia, Azithromycin, Teicoplanin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
HTML Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Muhammad Ishaq
Articles by Nasir Ali Afsar
Articles by Syeda Urooj Riaz
Articles by Muslim Abbas
Articles by Muhammad Shariq Mukarram
Articles by Khizra Ishaq
Articles by Shifa Ishaq
Articles by Muhammad Sanowar Ali
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. 2024; 2(1): 21-29. doi:10.5455/JMRR.20231226053523

Web Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. https://www.wisdomgale.com/jmrr/?mno=182674 [Access: June 05, 2025]. doi:10.5455/JMRR.20231226053523

AMA (American Medical Association) Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. 2024; 2(1): 21-29. doi:10.5455/JMRR.20231226053523


Vancouver/ICMJE Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. (2024), [cited June 05, 2025]; 2(1): 21-29. doi:10.5455/JMRR.20231226053523


Harvard Style

Ishaq, M., Afsar, . N. A., Riaz, . S. U., Abbas, . M., Mukarram, . M. S., Ishaq, . K., Ishaq, . S. & Ali, . M. S. (2024) Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev, 2 (1), 21-29. doi:10.5455/JMRR.20231226053523


Turabian Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. 2024. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. Journal of Medical Research and Reviews, 2 (1), 21-29. doi:10.5455/JMRR.20231226053523


Chicago Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. "Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia." Journal of Medical Research and Reviews 2 (2024), 21-29. doi:10.5455/JMRR.20231226053523


MLA (The Modern Language Association) Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. "Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia." Journal of Medical Research and Reviews 2.1 (2024), 21-29. Print. doi:10.5455/JMRR.20231226053523


APA (American Psychological Association) Style

Ishaq, M., Afsar, . N. A., Riaz, . S. U., Abbas, . M., Mukarram, . M. S., Ishaq, . K., Ishaq, . S. & Ali, . M. S. (2024) Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. Journal of Medical Research and Reviews, 2 (1), 21-29. doi:10.5455/JMRR.20231226053523


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesTerms of UseLicense InformationCopyright Information

About Journal of Medical Research and Reviews

Journal of Medical Research and Reviews is an international, peer-reviewed, open access journal, providing a platform for advances in basic, translational ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

Your comments are very important to us

We welcome your ideas, suggestions, comments, or questions. To reach Editorial Board please use one of the methods provided below.
 

Emails:

info@wisdomgale.com
editorinchief@ejmanager.com

Office Address:
WisdomGale Publishing
14 Rue de Grand-Bigard,
1082 Brussels
Belgium
 
We will respond within 48 to 72 hours.
 
Change of address or personal information? Please visit your account at www.ejmanager.com to update your information.